Pharmacologic management of isolated low high-density lipoprotein syndrome

American Journal of Therapeutics

Volumn 15, Issue 4, 2008, Pages 377-388

  Bermúdez, Valmore ^a   Cano, Raquel ^a   Cano, Clímaco ^a   Bermúdez, Fernando ^a   Arraiz, Nailet ^a   Acosta, Luis ^a   Finol, Freddy ^a   Pabón, María Rebeca ^a   Amell, Anilsa ^a   Reyna, Nadia ^a   Hidalgo, Joaquin ^a   Kendall, Paúl ^a   Manuel, Velasco ^b   Hernández, Rafael ^c  

^a UNIVERSIDAD DEL ZULIA   (Venezuela)

^b UNIVERSIDAD CENTRAL DE VENEZUELA   (Venezuela)

^c UNIVERSIDAD CENTROCCIDENTAL LISANDRO ALVARADO   (Venezuela)

Author keywords

Atherosclerosis; Cholesterol; Coronary artery disease; Dyslipidemia; HDLc; Reverse cholesterol transport

Indexed keywords

2 METHYLPROPANETHIOIC ACID S [2 [1 (2 ETHYLBUTYL)CYCLOHEXYLCARBOXAMIDO]PHENYL] ESTER; ACETYLSALICYLIC ACID; ANTIOXIDANT; APOLIPOPROTEIN A1; APOLIPOPROTEIN A1 MILANO; APP 018; ATORVASTATIN; BEZAFIBRATE; CHOLESTEROL ESTER TRANSFER PROTEIN; CIPROFIBRATE; CLOFIBRATE; D 4F; D 5F; ETHOFIBRATE; FENOFIBRATE; FIBRIC ACID DERIVATIVE; FISH OIL; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HUMAN GROWTH HORMONE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; MEVINOLIN; NICOTINIC ACID; PLACEBO; POLYGLACTIN; PRAVASTATIN; RECOMBINANT PROTEIN; ROSUVASTATIN; SIMVASTATIN; TORCETRAPIB; UNCLASSIFIED DRUG; UNINDEXED DRUG; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ALCOHOL CONSUMPTION; ARTERY DISEASE; ARTICLE; ATHEROSCLEROTIC CARDIOVASCULAR DISEASE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CORONARY ARTERY ATHEROSCLEROSIS; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DIETARY FIBER; DRUG DOSE COMPARISON; DRUG FATALITY; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DYSLIPIDEMIA; ERECTILE DYSFUNCTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART INFARCTION; HEPATITIS; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTRIGLYCERIDEMIA; IN-STENT RESTENOSIS; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; LIPOPROTEIN METABOLISM; LONGEVITY; LOW DRUG DOSE; LOW HIGH DENSITY LIPOPROTEIN SYNDROME; MYOSITIS; NONHUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN STRUCTURE; RASH; SIDE EFFECT; SMOKING CESSATION; STROKE; SUDDEN DEATH; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT; WEIGHT REDUCTION; BLOOD; CONTROLLED CLINICAL TRIAL; DRUG EFFECT; FEMALE; LIFESTYLE; MALE; PREVALENCE; REVIEW; RISK FACTOR; SYNDROME; UNITED STATES;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; CONTROLLED CLINICAL TRIALS AS TOPIC; DYSLIPIDEMIAS; FEMALE; HUMANS; LIFE STYLE; MALE; PREVALENCE; RISK FACTORS; SYNDROME; UNITED STATES;

EID: 51649098844     PISSN: 10752765     EISSN: None     Source Type: Journal    
DOI: 10.1097/MJT.0b013e318169bc0b     Document Type: Article

References (84)

1. Nofer J, Kehrel B, Fobker M, et al. HDL and arteriosclerosis: beyond reverse cholesterol transport. Atherosclerosis. 2002;161:1-16.
2. Toth P. High-density lipoprotein and cardiovascular risk. Circulation. 2004;109:1809-1812.
3. Johnson CL, Rifkind BM, Sempos CT, et al. Declining serum total cholesterol levels among US adults: the National Health and Nutrition Examination Surveys. JAMA. 1993;269:3002-3008.
4. Rubins HB, Robins SJ, Collins D, et al. Distribution of lipids in 8,500 men with coronary artery disease. Department of Veterans Affairs HDL Intervention Trial Study Group. Am J Cardiol. 1995;75:1196-1201.
5. Manninen V, Elo MO, Frick MH, et al. Lipid alterations and decline in the incidence of coronary heart disease in the Hadsinki Heart Study. JAMA. 1988;260:641-651.
6. Lewis GF, Rader DJ. New insights into the regulation of HDL metabolism and reverse cholesterol transport. Circ Res. 2005;96:1221-1232.
7. Mardi M, Brooks-Wilson A, Clee SM, et al. Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet. 1999;354:1341-1346.
8. Clee SM, Kastelein JJ, van Dam M, et al. Age and residual cholesterol efflux affect HDL cholesterol levels and coronary artery disease in ABCA1heterozygotes. J Clin Invest. 2000;106:1263-1270.
9. Jonas A. Lecithin cholesterol acyltransferase. Biochim Biophys Acta. 2000;1529:245-256.
10. Trigatti B, Covey S, Rizvi A. Scavenger receptor class B type I in high-density lipoprotein metabolism, atherosclerosis and heart disease: lessons from gene-targeted mice. Biochem Soc Trans. 2004;32:116-120.
11. Trigatti BL, Krieger M, Rigotti A. Influence of the HDL receptor SR-BI on lipoprotein metabolism and atherosclerosis. Arteriosder Thromb Vasc Biol. 2003;23:1732-1738.
12. Thuahnai ST, Lund-Katz S, Williams DL, et al. Scavenger receptor class B, type I-mediated uptake of various lipids into cells. Influence of the nature of the donor particle interaction with the receptor. J Biol Chem. 2001;276:43801-43808.
13. Webb NR, Cai L, Ziemba KS, et al. The fate of HDL particles in vivo after SR-BI-mediated selective lipid uptake. J Lipid Res. 2002;43:1890-1898.
14. Shaul P, Mineo C. HDL action on the vascular wall: is the answer NO? J Clin Invest. 2004;113:509-513.
15. Xia P, Vadas MA, Rye KA, et al. High density lipoproteins (HDL) interrupt the sphingosine kinase signaling pathway. A possible mechanism for protection against atherosclerosis by HDL. J Biol Chem. 1999;274:33143-33147.
16. Pomerantz KB, Fleisher LN, Tall AR, et al. Enrichment of endothelial cell arachidonate by lipid transfer from high density lipoproteins: relationship to prostaglandin 12 synthesis. J Lipid Res. 1985;26:1269-1276.
17. Nofer J, Levka B, Wolinska I, et al. Suppression of endothelial cell apoptosis by high density lipoproteins (HDL) and HDL-associated lysosphingolipids. J Biol Chem. 2001;276:34480-34485.
18. Aviram M, Rosenblat M, Boggier CL, et al. Paraoxonase inhibits high-density lipoprotein oxidation and preserves its functions. A possible peroxidative role for paraoxonase. J Clin Invest. 1998;101:1581-1590.
19. Mertens A, Holvoet P. Oxidized LDL and HDL: antagonists in atherothrombosis. FASEB J. 2001;15:2073-2084.
20. Attie DA, Kastelein JP, Hayden MR. Pivotal role of ABC-A1 in reverse cholesterol transport influencing HDL levels and susceptibility to atherosclerosis. J Lipid Res. 2001;42:1717-1726.
21. Acton S, Rigott A, Landschulz KT, et al. Identification of scavenger-receptor SR-B1 as a high density lipoprotein receptor. Science. 1996;271:518-520.
22. Goldbourt U, Yaari S, Medalic JH. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality: a 21-year follow-up of 8000 men. Arterioscler Thromb Vasc Biol. 1997;17:107-113.
23. Levinson SS. High density- and beta-lipoprotein screening for risk of coronary artery disease in the context of new findings on reverse cholesterol transport. Ann Clin Lab Sci. 2002;32:123-136.
24. Gordon D, Rifkind BM. Current concepts: high density lipoproteins - the clinical implications of recent studies. N Engl J Med. 1989;321:1311-1315.
25. International Task Force for Prevention of Coronary Heart Disease. Coronary heart disease: reducing the risk: the scientific background to primary and secondary prevention of coronary heart disease: a worldwide view. Nutr Metab Cardiovasc Dis. 1998;8:205-271.
26. Expert Panel on Detection, Evaluation and Treatment of High Blood Cholesterol in Adults. The second report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel II). Circulation. 1994;89:1329-1445.
27. Harper CR, Jacobson TA. New perspectives on the management of low levels of high density lipoprotein cholesterol. Arch Intern Med. 1999;159:1049-1057.
28. Von Eckardstein A, Assmann G. Prevention of coronary heart disease by raising of high density lipoprotein cholesterol? Curr Opin Lipidol. 2000;11:627-637.
29. Aguilar-Salinas C, Olaiz G, Valles V, et al. High prevalence of low HDL cholesterol concentrations and mixed hyperlipidemia in a Mexican nationwide survey. J Lipid Res. 2001;42:1298-1307.
30. Genest JJ, McNamara JR, Salem DN, et al. Prevalence of risk factors in men with premature coronary artery disease. Am J Cardiol. 1991;67:1185-1189.
31. Bolibar I, von Eckardstein A, Assmann G, et al, on behalf of the ECAT Angina Pectoris Study Group. Short-term prognostic value of lipid measurements for coronary events in patients with angina pectoris. Thromb Haemost. 2000;84:955-961.
32. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999;341: 410-418.
33. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
34. Brewer HB Jr. Increasing HDL cholesterol levels. N Engl J Med. 2004;350:15:1491-1494.
35. Gotto AM. Low high-density lipoprotein cholesterol as a risk factor in coronary heart disease: a working group report. Circulation. 2001;103;2213-2218.
36. Watts GF. Treating patients with low HDL cholesterol: choices, issues and opportunities. Curr Control Trials Cardiovasc Med. 2001;2:118-122.
37. Ellison RC, Zhang Y, Qureshi MM, et al. Lifestyle determinants of highdensity lipoprotein cholesterol: the National Heart, Lung, and Blood Institute Family Heart Study. Am Heart J. 2004;147:529-535.
38. Maeda K, Noguchi Y, Fukui T. The effects of cessation from cigarette smoking on the lipid and lipoprotein profiles: a metaanalysis. Prev Med. 2003;37:283-290.
39. Wakabayashi I. Relationship of body mass index with blood pressure and serum cholesterol concentrations at different ages. Aging Clin Exp Res. 2004;16:461-466.
40. Ashen MD, Blumenthal RS. Low HDL cholesterol levels. N Engl J Med. 2005;353:12:1252-1260.
41. King AC, Haskell WL, Young DR, et al. Long-term effects of varying intensities and formats of physical activity on participation rates, fitness, and lipoproteins in men and women aged 50 to 65 years. Circulation. 1995;91:2596-2604.
42. Rimm EB, Williams P, Fosher K, et al. Moderate alcohol intake and lower risk of coronary heart disease: metaanalysis of effects on lipids and haemostatic factors. BMJ. 1999;319:1523-1528.
43. Kim SY, Song HJ, Lee YY, et al. Biomedical issues of dietary fiber - glucan. J Korean Med Sci. 2006;21:781-789.
44. Kromhout D. Changes in energy and macronutrients in 871 middle-aged men during 10 years of follow-up (the Zutphen Study). Am J Clin Nutr. 1983:287-294.
45. Bourdon I, Yokoyama W, Davis P, et al. Postprandial lipid, glucose, insulin, and cholecystokinin responses in men fed barley pasta enriched with betaglucan. Am J Clin Nutr. 1999;69:55-63.
46. Brown L, Rosner B, Willett WW, et al. Cholesterol-lowering effects of dietary fiber: a meta-analysis. Am J Clin Nutr. 1999;69:30-42.
47. Institute of Medicine of the National Academies. Dietary Reference Intakes. Proposed Definition of Dietary Fiber. Washington, DC: National Academies Press; 2001.
48. Braaten JT, Wood PJ, Scott FW, et al. Oat beta-glucan reduces blood cholesterol concentration in hypercholesterolemic subjects. Eur J Clin Nutr. 1994;48:465-474.
49. Nicolosi R, Bell SJ, Bistrian BR, et al. Plasma lipid changes after supplementation with b-glucan fiber from yeast. Am J Clin Nutr. 1999;70:208-212.
50. Ink S, Mathews R. Oatmeal and oat bran: heart health benefits and more. In: Yalpani M, ed. New Technologies for Healthy Foods and Nutraceuticals. Shrewsbury, MA: ALT Press; 1997:195-233.
51. Reyna-Villasmil N, Bermudez-Pirela V, Mengual-Moreno E, et al. Oat-derived b-glucan significantly improves HDLC and diminishes LDLC and non-HDL cholesterol in over-weight individuals with mild hypercholesterolemia. Am J Ther. 2007;14:203-212.
52. Reyna N, Cano C, Bermudez V, et al. Sweeteners and beta-glucans improve metabolic and anthropometries variables in well controlled type 2 diabetic patients. Am J Ther. 2003;10:438-443.
53. Knopp RH. Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing. Am J Cardiol. 1998;82:24U-28U.
54. Jin F-Y, Kamanna VS, Kashyap M. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 1997;17:2020-2028.
55. Rader DJ. Effects of nonstatin lipid drug therapy on high-density lipoprotein metabolism. Am J Cardiol. 2003; 91(Suppl):18E-23E.
56. Guyton JR. Effects of niacin on atherosclerotic cardiovascular disease. Am J Cardiol. 1998;82:18U-23U.
57. Carlson LA, Rosenhamer G. Reduction of mortality in the Stockholm Ischaemic Heart Disease Secondary Prevention Study by combined treatment with clofibrate and nicotinic acid. Acta Med Scand. 1988;223:405-418.
58. McKenney J. New perspectives on the use of niacin in the treatment of lipid disorders. Arch Intern Med. 2004;164: 697-705.
59. Capuzzi DM, Guyton JR, Morgan JM, et al. Efficacy and safety of an extended-release niacin (Niaspan): a longterm study. Am J Cardiol. 1998;82:74U-81U.
60. Zema MJ. Gemfibrozil, nicotinic acid and combination therapy in patients with isolated hypoalphalipoproteinemia: a randomized, open-label, crossover study. J Am Coll Cardiol. 2000;35:640-646.
61. Illingworth DR, Stein EA, Mitchel YB, et al. Comparative effects of lovastatin and niacin in primary hypercholesterolemia. A prospective trial. Arch Intern Med. 1994;154: 1586-1595.
62. Sprecher DL. Raising high-density lipoprotein cholesterol with niacin and fibrates: a comparative review. Am J Cardiol. 2000;86(Suppl):46L-50L.
63. Ide T, Oku H, Sugano M. Reciprocal responses to clofibrate in ketogenesis and triglyceride and cholesterol secretion in isolated rat liver. Metabolism. 1982;31:1065-1072.
64. Nikkila EA, Huttunen JK, Ehnholm C. Effect of clofibrate on postheparin plasma triglyceride lipase activities in patients with hypertriglyceridemia. Metabolism. 1977;26:179-186.
65. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093.
66. van der Hoogt C, de Haan W, Westerterp M, et al. Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression. J Lipid Res. 2007; 48:1763-1771.
67. Knopp RH, Brown WV, Dujovne CA, et al. Effects of fenofibrate on plasma lipoproteins in hypercholesterolemia and combined hyperlipidemia. Am J Med. 1987;83: 50-59.
68. Aguilar-Salinas CA, Assis-Luores-Vale A, Stockins B, et al. Ciprofibrate therapy in patients with hypertriglyceridemia and low high density lipoproteins cholesterol in subjects with excess body weight (The CIPROMAM-LAT STUDY). Heart Views. 2004;5:47-53.
69. Bermudez-Pirela V, Souki A, Cano-Ponce C, et al. Ciprofibrate treatment decreases non-high density lipoprotein cholesterol and triglycerides and increases high density lipoprotein cholesterol in patients with Frederickson type IV dyslipidemia phenotype. Am J Ther. 2007; 14:213-220.
70. Fruchart J-C, Duriez P. HMG CoA reductase inhibitors and PPAR-α activators: are their effects on high-density lipoprotein cholesterol and their pleiotropic effects clinically relevant in prevention trials? Curr Atheroscl Rep. 2002;4:403-404.
71. Downs JR, Clearfield M, Weiss S, et al. For the AFCAPS/TexCAPS Research Group. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. JAMA. 1998;279: 1615-1622.
72. Pyorala K, Pedersen TR, Kjekshus J, et al. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20:614-620.
73. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996;335:1001-1009.
74. Goldberg RB, Mellies MJ, Sacks FM, et al. Cardiovascular events and their reduction with pravastatin in diabetic and glucoseintolerant myocardial infarction survivors with average cholesterol levels: Subgroup analyses in the cholesterol and recurrent events (CARE) trial. The Care Investigators. Circulation. 1998;98:2513-2519.
75. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339:1349-1357.
76. Choice of lipid-lowering drugs. Med Lett Drugs Ther. 1998; 40:117-122.
77. Corsini A, Bellosta S, Baetta R, et al. New insights into the pharmacodynamic and pharmacokinetic properties of statins. Pharmacol Ther. 1999;84:413-428.
78. Shepherd J. Raising HDL cholesterol and lowering CHD risk: does intervention work? Eur Heart J. 2005;7(Suppl F): F15-F22.
79. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med. 2001;345: 1583-1592.
80. Jhon C. Evidence-based management of dyslipidemias in women. Curr Atheroscl Rep. 2003;5:379-385.
81. Brousseau, ME; Schaefer EJ, Wolfe ML, et al. Effects of an inhibitor of cholesteryl ester transfer protein on HDL cholesterol. N Engl J Med. 2004;350:1505-1515.
82. Barter PJ, Caulfield M, Eriksson M, et al, for the ILLUMINATE Investigators. Effects of torcetrapib in patients at high risk for coronary events. N Eng J Med. 2007;357:2109-2122.
83. Nissen SE, Tsunoda T, Tuzcu EM, et al. Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial. JAMA. 2003;290:2292-2300.
84. Navab M, Srinivasa A, Hough GMG, et al. Apolipoprotein A-I mimetic peptides. Arterioscler Thromb Vasc Biol. 2005;25:1325-1331.